$ALNY

INSTITUTIONAL QUANT REPORT

Constitution Metrics (S-GRADE)

ROE

96.6%

S&P 500 Alpha: 6.4x

ROIC

122.9%

Cash Holdings

$0.0

AI 전문 투자 리포트

🔥 [AI Catalyst] The 100x return secret created by focusing on ROIC Alnylam Pharmaceuticals (ALNY) stands out with an extraordinary return on equity of 96.56% and a remarkable return on invested capital nearing 123%. Its elite quant score reflects its potential for substantial growth, making it a compelling investment opportunity in the biotech sector.

Bull Case (상승 모멘텀)

["Exceptional ROIC: Alnylam's return on invested capital is strikingly high at 122.89%, indicating efficient capital use and a strong potential for profitability on investments made, which could lead to significant future cash flows.","Attractive Valuation Metrics: With a PEG ratio of 0.28, the stock appears undervalued relative to its growth potential, suggesting that investors may be able to purchase future earnings at a bargain price, amplifying potential returns.","Strong Financial Position: The company boasts a robust net cash position of over $3.3 billion, providing substantial liquidity to fund growth initiatives, research, and development, or to weather market fluctuations."]

Bear Case (주의/리스크 요인)

["Growth Concerns: The company's 5-year compound annual growth rate (CAGR) stands at 0.00%, raising questions about future revenue expansion and the sustainability of its high ROIC in the absence of sales growth.","Lack of Revenue Growth Metrics: With no current revenue growth data available, it is uncertain how Alnylam will maintain its high profitability levels as market dynamics evolve, leaving investors wary.","Value Trap Risk: Given that the company has not demonstrated consistent revenue growth, there exists a risk that while the high ROE and ROIC look appealing, they may not translate into long-term value creation, flagging a potential 'Value Trap' scenario."]

마지막 분석: 10/4/2026